Laia Mariné will share “Epigenomic insights into post-stroke respiratory infections: a DNA methylation study” as part of the e-poster sessions.
Elena Muiño will present “Single-cell RNA sequencing reveals endothelial transcriptomic changes in CADASIL human samples” as part of the e-poster sessions.

Paula Boldo will present “Sex-stratified genetic risk of stroke: findings from an X-chromosome-wide association study” in the Free Communication 06: Disparities, Implementation, KT, AI session (Wed, 22 Oct – 15:00–16:30, Room 115).

Don't miss the phenomenal work of the rest of the Stroke Pharmacogenomics and Genetics team

Laia Llucià will present “A case-control proteomic study using the Olink Explore panel identifies 640 proteins associated with ischemic stroke risk” in the Basic Science and Biomarkers e-poster session

You can also catch me earlier that day (11:45 - Station 04) in the Basic Science and Biomarkers poster session, where I’ll be presenting new findings from our Stopped-Stroke project:
“Differential methylation and variability methylation reveal specific stroke-associated epigenetic signatures.”

Thanks to all the researchers involved in this work, but specially @RobynneBraun for proposing and leading this initiative.

Stroke recovery is very complex. By aligning how we obtein and process biospecimens, we create a foundation for international collaboration an identification of strong biomarker candidates for future treatments

This work updates and expands the previous Iternational Stroke Genomics Consortium recomendations, incorporating the latest advances in genomic, epigenomic, protemomics and more for biomarker identification.

With consistent methods, we can:
🔹 Build global biobanks for large-scale research
🔹 Uncover biology of stroke recovery
🔹 Identify genetic & molecular predictors of outcomes
🔹 Find new therapeutic targets

Why does this matter?

Until now, protocols varied widely, making it difficult to combine data across centers. Our guidelines harmonize approaches to empower both large & smaller hospitals and reserch institution to contribute and collaborate.

Yey! I'll try to attend although it will be almost midnight where I am. Perks of been a night owl.

#EpiSci #EpigeneticsSci #Epigenetics #Epigenomics #academi

Unlike genetics, epigenetics is modifiable, making it a promising drug target. Epigenetic drugs could be a game-changer for stroke.
Some promissing potetntal treatments are: DNMT inhibitors, HDAC inhibitors, HMTi/HDMi) and CRISPRoff/CRISPRon
#Stroke #DNAmethylation #Epigenomics

Challenges remain including the reliance on blood samples variability in collection timepoints relatively small sample sizes lack of longitudinal studies and limited multi-ethnic research
Addressing these gaps is crucial to confirming findings and develop effective therapies

Higher biological age predicts 3-month mortality and worse functional outcomes post-stroke.
Stroke survivors with a new ischemic event within 3 months were biologically older by ~2 years than those without recurrence

DNAm can estimate #biologicalage, which may predict stroke risk, severity, and outcomes better than chronological age.
Stroke patients tend to be biologically older than their actual age.
This effect seem to be stronger in men and vary by stroke type

Findings suggest distinct pathways influence prognosis at different time points
Mid-term outcomes are linked to #excitotoxicity aligning with prior GWAS
Long-term outcomes maigth involve #angiogenesis
Recurrence seems associated with #coagulation